Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Stockpiling Priority Review Vouchers

Executive Summary

Firm picks up second PRV with purchase from Ultragenyx, which is expected to use the $130m to help advance its rare disease development pipeline.

You may also be interested in...



Novartis’ Attention To Tropical Diseases Pays Off: Liver Fluke Drug Egaten Earns Priority Review Voucher

US FDA approval expected to facilitate global use of one-day oral treatment of fascioliasis, a designated neglected tropical disease, which Novartis developed with the World Health Organization.

Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar

The latest drug development news and highlights from our US FDA Performance Tracker.

Priority Review Voucher Sales Prices Level Off In 2017

BioMarin's sale of voucher earned with approval of rare pediatric disease drug Brineura the fourth publicly disclosed voucher sale this year with a price tag between $125m and $150m.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS122167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel